Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899548 · ClinicalTrials.gov registry record
DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer
A clinical trial, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- 182
- Enrollment target
NCT00899548 is a clinical trial that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 182 participants.
The verdict
NCT00899548 has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- 182 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to systemic therapy. PURPOSE: This laboratory study is looking at DNA in predicting response after systemic therapy in women with metastatic breast cancer.
Interventions
- GENETIC microarray analysis
- OTHER laboratory biomarker analysis
- GENETIC polymerase chain reaction
- GENETIC DNA methylation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2007-01 |
| Est. Completion | 2016-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00899548
The ClinicalTrials.gov registry entry for NCT00899548 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which microarray analysis is the first listed.
NCT00899548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00899548 about?
NCT00899548 is a clinical study titled "DNA in Predicting Response After Systemic Therapy in Women With Metastatic Breast Cancer". RATIONALE: Studying samples of blood from patients with cancer and from healthy participants in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how well patients will respond to systemic therap...
What is the current status of trial NCT00899548?
This trial is currently completed. The enrollment target is 182 participants. The study started on 2007-01. Estimated completion is 2016-10.
What interventions are being tested in trial NCT00899548?
The interventions under investigation include: microarray analysis (GENETIC), laboratory biomarker analysis (OTHER), polymerase chain reaction (GENETIC), DNA methylation analysis (GENETIC).
Who is sponsoring clinical trial NCT00899548?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.